by David Cassak
Admittedly, the medical device industry is never likely to equal the number of companies that went public in 1996, when...
Jomed's Rising Star
Over the past three years, Jomed's sales growth has been dramatic, as the company has challenged market leaders like Guidant and AVE in the European stent marketplace. But, unlike other small cardiovascular start-ups, Jomed won't be content with a strong stent business--it is actively engaged in building a broad-based cardiovascular business that is truly global..
More from Business Strategy
More from In Vivo
• By
When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.
• By
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
• By
Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.